透云生物(01332)发布中期业绩，股东应占溢利1124.3万港元 同比扭亏为盈

Core Viewpoint - The company reported a significant decrease in revenue but achieved profitability compared to the previous year, primarily due to gains from financial assets measured at fair value [1] Financial Performance - Revenue for the six months ending June 30, 2025, was HKD 36.581 million, a year-on-year decrease of 20.82% [1] - Profit attributable to owners was HKD 11.243 million, contrasting with a loss of HKD 47.969 million in the same period last year [1] - Earnings per share were HKD 0.004 [1] Factors Influencing Performance - The increase in profitability was mainly attributed to the rise in fair value gains from financial assets recognized in profit or loss [1]